Immuneering Corp IMRX
- atebimetinib — Pancreatic Ductal Adenocarcinoma Phase 3
- atebimetinib — Advanced Solid Tumors Phase 1
MAPK pathway (1 companies · 2 programs)
Companies with an active program directed at MAPK pathway.
Companies with an active program directed at MAPK pathway.